The first paper that I would like to point out to our readers is
“Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the Literature”, published in Medicine; May 2014; Vol. 93; Issue 3 ; p. 121-134.
The possibility to detect with MR neuroimaging DRG abnormalities in patients “with neuropathic pain who do not have markers or peripheral neuropathy”, that is with normal skin biopsy studies, is to me an important break-through. I am also quite curious to know the diagnosis that these patients received when their painful condition did not find a positive background in skin biopsy. I bet that the condition was labelled as “functional”.
The second paper that I like to signal to Neuropenews readers has been presented in the Joint Congress of European Neurology in Istanbul:
It is the Abstract OS1115 (How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial), to be confronted with the Abstracts OS4202 (Patients who switch to natalizumab have better outcomes than those who continue on the same platform therapy after a relapse) and OS4203 (After a relapse, patients who switch to natalizumab have better outcomes than those who switch between platform therapies). All these reports are related to natalizumab. It appears that switching OFF the natalizumab is definitely not easy and possibly not safe. It appears that patients who present ONE relapse when threated with IF and who are switched TO natalizumab , they have a better outcome.
My absolutely personal comment is that all these studies are fully supported by “BIG PHARMA”, and I leave it to the readers to make up their own mind.